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Abstract 
Background: Atypical hemolytic uremic 
syndrome (aHUS) may present in either the 
antepartum or postpartum period and is often 
indistinguishable from other pregnancy-
associated diseases. Timely recognition and 
appropriate treatment can greatly reduce 
maternal morbidity and mortality. 
Cases: This case series describes two cases of 
aHUS in the post-partum period, the difficulty in 
distinguishing the diagnosis, and the 
implementation of appropriate treatment with 
eculizumab, a terminal complement inhibitor. 
Conclusion: As a terminal complement inhibitor, 
eculizumab, has been shown to significantly 
improve clinical and long term renal outcomes, 
early diagnosis of aHUS is increasingly 
important. These two cases of aHUS 
demonstrate the path of accurate diagnosis and 
timely initiation of therapy to maximize the 
possibility of patient recovery. 
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This case series describes atypical 
hemolytic uremic syndrome (aHUS), a 
rare complication in the post-partum 
period, which may lead to lifelong 
complications or even maternal 
mortality. Clinical signs and laboratory 
findings may make the diagnosis difficult 
due to similarities with other post-partum 
processes such as acute fatty liver of 
pregnancy (AFLP), hemolytic anemia, 
elevated liver enzymes, and low 
platelets (HELLP) syndrome and 
thrombotic thrombocytopenic purpura 
(TTP). The importance of placing aHUS 
on the differential in the antepartum and 
postpartum period is paramount for 
obstetricians, and care of these patients 
requires a multi-disciplinary approach. 
Newer therapies and possible genetic 
variants contributing to aHUS have 
improved outcomes and directed further 
care for patients. Expeditious diagnosis 
and implementation of therapy or 
referral to a center that can provide care 
can be the difference between life or 
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death for these patients. 
Case 1: 
A 30 year old G1P0 was admitted to the 
labor and delivery unit for a scheduled 
cesarean section at 39w0d gestation 
due to breech presentation. The patient 
underwent an uncomplicated procedure 
and delivered a healthy female infant. 
The patient had an uncomplicated post-
partum course until post-operative day 
(POD) 3. On POD3 she had general 
malaise, body aches, nausea and an 
episode of emesis. Vital signs were 
unremarkable. Later that day, she 
became acutely jaundiced. Laboratory 
tests revealed a white blood count 
(WBC) of 29.4 K/mm3 and elevated total 
bilirubin of 25.9 mg/dL. The remainder 
of her liver panel laboratory values were 
hemolyzed on multiple draws. 
Peripheral blood smear was also 
concerning for hemolysis with many 
schistocytes present. Hemoglobin 
dropped from 11.7 to 10.4 g/dL and 
platelets decreased from 154 to 89 
K/mm3. Her PT was 30 seconds, INR 
3.1, PTT 45 seconds, and fibrinogen 67 
mg/dL. LDH was 6600 U/L. She was 
also noted to have acute kidney injury 
with a creatinine (Cr) of 2.3 mg/dL. Due 
to concern for acute liver failure and 
disseminated intravascular coagulation 
(DIC), the patient was transferred to the 
Surgical and Neurosurgical Intensive 
Care Unit. A right upper quadrant 
ultrasound revealed mildly elevated 
extrahepatic biliary dilatation and mild 
hepatosplenomegaly. The initial 
differential diagnosis included AFLP, 
HELLP syndrome, atypical TTP-HUS or 
an infectious process. She was started 
on magnesium sulfate for seizure 
prophylaxis, which was shortly 
thereafter stopped due to 
hypermagnesemia from decreased renal 
excretion. She was empirically started 
on piperacillin/tazobactam and acyclovir 
as the etiology of her disease process 
remained unknown and infectious 
causes remained in the differential 
diagnosis. Two units of fresh frozen 
plasma, two units of packed red blood 
cells, and one unit of cryoprecipitate 
were administered to correct her DIC. 
PRBCs were given as needed to keep 
her Hgb above 7.0 g/dL. 
The patient was anuric over the next 24 
hours and also developed 
encephalopathy with symptoms of 
fatigue, lethargy, and confusion. She 
was initiated on hemodialysis on POD5 
due to encephalopathy, metabolic 
acidosis, hypervolemia, and 
hypermagnesemia in the setting of 
anuric renal failure.   
As her clinical picture evolved, it 
appeared to be more consistent with 
aHUS due to progressively worsening 
renal failure and persistently severe 
thrombocytopenia. C3 complement 
levels were also collected and were 
noted to be mildly low at 83 mg/dL. She 
was started on eculizumab, a 
complement inhibitor, on POD6 as 
treatment for presumed aHUS. Her 
platelets began to rise after eculizumab 
initiation and recovered from 36 to 190 
k/mm3 within 72 hours. She was started 
on prophylaxis for meningitis with 
penicillin VK due to the complement 
blocking effects of the eculizumab and 
the complement mediated immune 
response required for defense from 
encapsulated organisms. She also 
received vaccinations for hemophilus 
influenzae, meningococcus, and 
pneumococcus. Eculizumab was started 
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at 900 mg intravenously weekly for four 
weeks and then increased to 1200 mg 
intravenously every 2 weeks. 
The hepatology service was consulted 
and completed an extensive work up for 
liver failure, which returned negative for 
all infectious, autoimmune, and drug 
related causes. ADAMST13 returned 
normal, ruling out TTP. Her AST/ALT 
reached maximum on POD4 to 
1311/244 U/L and then trended 
downwards. 
A renal biopsy confirmed the diagnosis 
of aHUS with findings consistent with 
changes of acute thrombotic 
microangiopathy including areas of 
acute tubular necrosis, fibrin thrombi in 
capillary loops, and cortical necrosis 
(Figure 1). Glomerular staining was 
negative for IgG, IgA, IgM, C3 and C1q, 
ruling out other etiologies of 
immunopathologic glomerulonephritis. 
The patient continued to be anuric at 
discharge and remained on dialysis 
three times a week. She continued 
eculizumab therapy as an outpatient.  
She underwent genetic testing and was 
not found to have a classic gene 
mutation for aHUS, including 
complement factor H (CFH), membrane 
cofactor protein (MCP), factor I (IF), and 
auto-antibodies against CFH-Ab. Her 
renal function did not improve with 
eculizumab therapy and she underwent 
a renal transplant six months after her 
initial presentation and is doing well. 
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Figure 1. Renal biopsy results revealing changes consistent with acute 
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Case 2: 
A 30 year old G1P0 at 34w4d presented 
to the labor and delivery unit due to 
concern for preeclampsia. She had a 
diagnosis of gestational hypertension 
and had completed a 24 hour urine 
protein which returned at 798 mg. She 
was admitted for observation due to a 
diagnosis of preeclampsia without 
severe features. At 34w6d, she had 
severe range blood pressures as well as 
elevated AST/ALT of 41/41 U/L, meeting 
criteria for preeclampsia with severe 
features. She underwent an induction of 
labor and was started on magnesium 
sulfate for seizure prophylaxis. 
During her induction course, she 
developed epigastric pain and 
increasing AST/ALT of 156/147 U/L. 
Other HELLP laboratory values 
remained stable at this time with 
platelets 206 K/mm3 and Cr 0.7 mg/dL. 
The decision was made to proceed with 
delivery via cesarean section due to 
worsening preeclampsia with severe 
features remote from delivery. She 
underwent an uncomplicated procedure, 
producing a healthy male infant. 
She was continued on magnesium 
sulfate for 24 hours after delivery. She 
continued to have severe range blood 
pressures, which were responsive to 
antihypertensive medications. HELLP 
laboratory values were trended every 6 
hours with liver function tests reaching a 
maximum of AST 2993 U/L, ALT 1600 
U/L. Her platelets additionally dropped 
to a nadir of 40 k/mm3 and her Cr rose 
to 1.4 mg/dL, accompanied by oliguria. 
Due to lower extremity numbness and a 
magnesium level of 8.6 mg/dL, 
magnesium sulfate was discontinued. 
Her hemoglobin also dropped from 10.1 
to 7.7 g/dL, despite being given 1 unit of 
packed red blood cells in the interim. A 
RUQ ultrasound was obtained without 
any evidence of liver hematoma or other 
abnormalities. 
Nephrology was consulted on POD2 
due to continued rise of Cr to 3.0 mg/dL, 
hyperkalemia, and decreased UOP. Due 
to concern for TTP versus aHUS versus 
HELLP, complement levels, 
haptoglobin, LDH, ADAMTS13, and 
urine studies were obtained. 
Complement levels returned low, LDH 
was elevated, and haptoglobin was 
undetectable, concerning for thrombotic 
microangiopathy secondary to aHUS. 
The decision was made to start 
eculizumab therapy. ADAMTS13 did 
return normal at 81% (normal >60%), 
ruling out the diagnosis of TTP.  
The patient’s renal function continued to 
decline and decision was made to start 
dialysis due to electrolyte abnormalities. 
Over the next few days, her platelets 
significantly improved from 80 to 105 
K/mm3 suggesting therapy with 
eculizumab was effective. She was 
discharged on POD8 with plans for 
outpatient hemodialysis twice weekly 
and weekly eculizumab infusions.  
As an outpatient, she continued dialysis, 
eculizumab infusions, and follow up with 
Nephrology. Her creatinine improved, 
platelets returned to normal range, and 
her C3 normalized to >100 mg/dL. 
Dialysis was eventually stopped due to 
renal recovery. She underwent genetic 
testing which returned negative for any 
causative variants for aHUS. She 
currently continues on eculizumab 
treatment. 
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Conclusion 
aHUS has death rates as high as 25% 
and progression to end stage renal 
disease (ESRD) as high as 50%.1 As 
the two above case reports 
demonstrate, these outcomes make it 
important to recognize aHUS early, so 
the appropriate interventions can be 
made (Table 1). aHUS can be very 
difficult to differentiate from other 
diseases such as HELLP, AFLP, and 
TTP due to a significant overlap in 
symptoms and laboratory 
abnormalities.2 Of these diagnoses, TTP 
is unique in that it can often be 
differentiated, as it is generally related to 
an ADAMTS13 deficiency and most 
commonly occurs in the 2nd trimester.3 
Thrombotic microangiopathy (TMA) 
describes the process of endothelial cell 
injury and thrombus formation in the 
microvasculature. This leads to 
hemolytic anemia, non-immune 
thrombocytopenia, and organ failure.3 
TMA has been shown to occur in 1 per 
25,000 pregnancies and is a classic 
feature associated with HUS.4 
Classically, HUS is associated with 
bacterial infections with 
Enterohemorrhagic Escherichia Coli 
(EHEC). All non-EHEC–associate HUS 
is referred to as atypical HUS (aHUS).   
aHUS is often expressed in the setting 
of genetic or autoimmune defects in the 
complement system in combination with 
underlying complement amplifying 
conditions, including pregnancy and its 
complications. This is referred to as the 
‘multiple-hit’ hypothesis.3 In the post-
partum period, complement may be 
activated by maternal circulation of fetal 
cells, infection, hemorrhage, 
preeclampsia, and/or HELLP.4  
Underlying mutations in complement 
regulators or activators such as 
complement factor H (CFH), membrane 
cofactor protein (MCP), factor I (IF), and 
auto-antibodies against CFH-Ab are 
associated with aHUS.1,5 CFH, the main 
mediator of the alternative pathway of 
complement, is the most common 
genetic mutation in aHUS.3,5,6 Patients 
with an underlying complement defect 
are more susceptible to developing 
TMA.1 
Caprioli et al. completed a study of 
genetic analysis for CFH, MCP, and IF 
in 156 patients with aHUS.5 
Approximately 56% of these patients did 
not have any of these three mutations. 
This study determined that screening for 
known mutations in patients with aHUS 
may determine the success of 
subsequent renal transplant if needed. 
Patients with MCP mutations were 
found to have a remission rate of 80-
90% without treatment and to have the 
best prognosis.1 MCP is a 
transmembrane protein highly 
expressed in the kidney, which supports 
the idea that renal transplant would cure 
the disease. In the case of CFH and IF, 
these factors are mostly synthesized in 
the liver and recurrence rate for aHUS 
with these mutations is very high, 
approaching 100%, suggesting that a 
renal transplant may not be successful.  
Caproli et al. found that 6/7 patients with 
CFH and IF mutations had graft failure 
due to disease recurrence and 2/2 
patients with MCP mutations had a 
successful renal transplant.5 These data 
suggest that genetic screening in 
patients with aHUS may be important in 
counseling for recurrence and prognosis 
as well as determining successful renal 
transplant in those with ESRD. In our 
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cases, testing was completed at the 
Molecular Otolaryngology and Renal 
Research Laboratory at the University of 
Iowa. Both of the above patients 
underwent genetic testing and did not 
have evidence of a classical genetic 
mutation for aHUS. Therefore, for the 
patient in case 1, the recommendation 
was made for her to undergo renal 
transplantation from a non-related donor 
in the event there is an unknown genetic 
component to her aHUS. 
Multiple studies have described the use 
of plasma exchange therapy 
immediately after diagnosis of aHUS 
until hematologic parameters stabilize, 
followed by eculizumab therapy with 
good overall outcomes and renal 
recovery.2,7 It is thought that plasma 
exchange significantly increases 
survival rates by transiently correcting 
laboratory abnormalities, but ultimately 
complement inhibitors are necessary to 
improve renal recovery by inhibiting the 
underlying complement dysregulation.7 
Before the advent of eculizumab, 
plasma therapy was considered the 
mainstay of treatment with good survival 
rates but high rates of morbidity 
associated with end stage renal 
disease.1 Eculizumab is a humanized 
monoclonal antibody that arrests 
complement activation and progression 
of TMA by binding with high affinity to 
human C5 complement protein and 
preventing pro-inflammatory 
complement formation. Use of this 
therapy can lead to recovery of renal 
function over time, with the possibility of 
discontinuation of dialysis and 
avoidance of renal transplant, as noted 
in case 2.8 In a randomized control trial 
by Legendre et al. of 37 patients 
receiving eculizumab for aHUS, results 
revealed that eculizumab was 
associated with significantly improved 
clinical outcomes and that the sooner 
eculizumab is started, the better the 
improvement in renal function.8 This 
same study also found similar outcomes 
for patients regardless of treatment with 
plasma exchange.8 In our cases, the 
patients were started on eculizumab at 
different times. The first patient was 
started on POD6, as soon as disease 
progression revealed that aHUS was the 
more likely process due to persistent 
thrombocytopenia and worsening of 
renal function. The second patient was 
started on eculizumab on POD2 due to 
early suspicion of aHUS. The different 
renal function outcomes for each patient 
may support that earlier initiation of 
eculizumab, despite an unclear clinical 
picture, can be beneficial to the patient. 
Though it is important to consider that 
eculizumab can be cost prohibitive, at 
around $18,000 per dose, and has 
immunosuppressive properties, making 
correct diagnosis important. 
aHUS in the post-partum period is 
associated with significant maternal 
morbidity and mortality. Early diagnosis 
can be difficult due to overlap with other 
disease processes. These case reports 
demonstrate the importance of early 
diagnosis of aHUS and early 
administration of eculizumab (Table 1). 
When aHUS is considered a possible 
diagnosis, it may be beneficial to begin 
eculizumab therapy as early initiation 
has been shown to significantly improve 
outcomes. Genetic testing can be 
helpful in determining recurrence risk as 
well as outcomes of renal 
transplantation and should be 
considered for all patients with aHUS.  
For these patients, future pregnancies 
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are not recommended as the recurrence 
of aHUS can be high. 
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Table 1: Clinical presentation 
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